nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.05.2015 | Original Article – Clinical Oncology

The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients

verfasst von: Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Naminatsu Takahara, Kei Saito, Kazunaga Ishigaki, Tsuyoshi Hamada, Suguru Mizuno, Koji Miyabayashi, Keisuke Yamamoto, Dai Mohri, Hirofumi Kogure, Natsuyo Yamamoto, Hideaki Ijichi, Keisuke Tateishi, Minoru Tada, Kazuhiko Koike

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The role of local renin-angiotensin system (RAS) as a target for the treatment of pancreatic cancer has been increasingly reported, but the addition of candesartan, one of angiotensin system inhibitors (ASIs), to gemcitabine in our prospective trial failed to demonstrate activity against pancreatic cancer. The aim of this study was to explore subgroups that would benefit from the inhibition of RAS by the use of ASIs.

Methods

Consecutive patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy were retrospectively studied. Hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were estimated by a Cox proportional hazards model. Interactions between the use of ASIs and each subgroup were tested.

Results

Between 2001 and 2013, 349 patients received gemcitabine-based chemotherapy for advanced pancreatic cancer; 232 were metastatic, 210 received gemcitabine monotherapy, 108 took ASIs, 166 were never smokers and 188 were diabetic. The median PFS and OS were 4.9 and 11.2 months, respectively. When the effects of the use of ASIs were evaluated by a Cox proportional hazard model, there were two subgroups with P interaction <0.10 both in PFS and OS: never smokers and gemcitabine monotherapy. HRs for PFS and OS by the inhibition of RAS were 0.71 (P = 0.021) and 0.68 (P = 0.014) in never smokers and 0.70 (P = 0.027) and 0.77 (P = 0.124) in patients receiving gemcitabine monotherapy.

Conclusion

The inhibition of RAS in advanced pancreatic cancer might improve clinical outcomes in cases without a history of smoking or in cases receiving gemcitabine monotherapy.

Ager EI, Neo J, Christophi C (2008) The renin-angiotensin system and malignancy. Carcinogenesis 29:1675–1684. doi:10.1093/carcin/bgn171 CrossRefPubMed

Anderson MA et al (2012) Alcohol and tobacco lower the age of presentation in sporadic pancreatic cancer in a dose-dependent manner: a multicenter study. Am J Gastroenterol 107:1730–1739. doi:10.1038/ajg.2012.288 CrossRefPubMedCentralPubMed

Blackford A et al (2009) Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res 69:3681–3688. doi:10.1158/0008-5472.can-09-0015 CrossRefPubMedCentralPubMed

Bosetti C et al (2012) Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol 23:1880–1888. doi:10.1093/annonc/mdr541 CrossRefPubMedCentralPubMed

Brand RE et al (2009) Pancreatic cancer patients who smoke and drink are diagnosed at younger ages. Clin Gastroenterol Hepatol 7:1007–1012. doi:10.1016/j.cgh.2009.06.008 CrossRefPubMedCentralPubMed

Burris HA 3rd et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413PubMed

Conroy T et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825. doi:10.1056/NEJMoa1011923 CrossRefPubMed

Cote GA et al (2011) Alcohol and smoking as risk factors in an epidemiology study of patients with chronic pancreatitis. Clin Gastroenterol Hepatol 9:266–273. doi:10.1016/j.cgh.2010.10.015 CrossRefPubMedCentralPubMed

Dandona M, Linehan D, Hawkins W, Strasberg S, Gao F, Wang-Gillam A (2011) Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer. Pancreas 40:931–937. doi:10.1097/MPA.0b013e318215a9b1 CrossRefPubMed

Faehling M, Eckert R, Kuom S, Kamp T, Stoiber KM, Schumann C (2010) Benefit of erlotinib in patients with non-small-cell lung cancer is related to smoking status, gender, skin rash and radiological response but not to histology and treatment line. Oncology 78:249–258. doi:10.1159/000315731 CrossRefPubMed

Ijichi H et al (2006) Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 20:3147–3160. doi:10.1101/gad.1475506 CrossRefPubMedCentralPubMed

Kanai M et al (2009) A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. Ann Oncol 20:1397–1401. doi:10.1093/annonc/mdp008 CrossRefPubMed

Keizman D et al (2014) Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 19:51–60. doi:10.1634/theoncologist.2012-0335 CrossRefPubMedCentralPubMed

Khakoo AY, Sidman RL, Pasqualini R, Arap W (2008) Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis? Cancer Res 68:9112–9115. doi:10.1158/0008-5472.CAN-08-0851 CrossRefPubMed

Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Shin SW, Kim YH (2012) How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology 83:354–360. doi:10.1159/000337979 CrossRefPubMed

Kuno A et al (2003) Angiotensin-converting enzyme inhibitor attenuates pancreatic inflammation and fibrosis in male Wistar Bonn/Kobori rats. Gastroenterology 124:1010–1019. doi:10.1053/gast.2003.50147 CrossRefPubMed

Masamune A, Hamada S, Kikuta K, Takikawa T, Miura S, Nakano E, Shimosegawa T (2013) The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand J Gastroenterol 48:602–609. doi:10.3109/00365521.2013.777776 CrossRefPubMed

Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S (2004) Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 28:38–44CrossRefPubMed

Mizuno S et al (2014) Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Pancreas 43:1014–1017. doi:10.1097/mpa.0000000000000158

Moore MJ et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966. doi:10.1200/JCO.2006.07.9525 CrossRefPubMed

Nakai Y et al (2009) A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology 77:300–303. doi:10.1159/000259616 CrossRefPubMed

Nakai Y et al (2010) Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br J Cancer 103:1644–1648. doi:10.1038/sj.bjc.6605955 CrossRefPubMedCentralPubMed

Nakai Y et al (2012a) Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci 103:1489–1492. doi:10.1111/j.1349-7006.2012.02311.x CrossRefPubMed

Nakai Y et al (2012b) A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer 106:1934–1939. doi:10.1038/bjc.2012.183 CrossRefPubMedCentralPubMed

Nakai Y et al (2013) A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest New Drugs 31:1294–1299. doi:10.1007/s10637-013-9972-5 CrossRefPubMed

Nakai Y et al (2014) A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Cancer Chemother Pharmacol 74:911–915. doi:10.1007/s00280-014-2563-0

Okusaka T et al (2011) Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102:425–431. doi:10.1111/j.1349-7006.2010.01810.x CrossRefPubMed

Olson P, Hanahan D (2009) Cancer. Breaching the cancer fortress. Science (New York, NY) 324:1400–1401. doi:10.1126/science.1175940 CrossRef

Olson SH et al (2010) Allergies, obesity, other risk factors and survival from pancreatic cancer. Int J Cancer 127:2412–2419. doi:10.1002/ijc.25240 CrossRefPubMed

O’Malley M, Healy P, Daignault S, Ramnath N (2013) Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors. Oncology 85:216–222. doi:10.1159/000355107 CrossRefPubMed

Pelucchi C et al (2014) Smoking and body mass index and survival in pancreatic cancer patients. Pancreas 43:47–52. doi:10.1097/MPA.0b013e3182a7c74b CrossRefPubMed

Shimizu K (2008) Mechanisms of pancreatic fibrosis and applications to the treatment of chronic pancreatitis. J Gastroenterol 43:823–832. doi:10.1007/s00535-008-2249-7 CrossRefPubMed

Tsao AS, Liu D, Lee JJ, Spitz M, Hong WK (2006) Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer 106:2428–2436. doi:10.1002/cncr.21884 CrossRefPubMed

van Geenen EJ, Smits MM, Schreuder TC, van der Peet DL, Bloemena E, Mulder CJ (2011) Smoking is related to pancreatic fibrosis in humans. Am J Gastroenterol 106:1161–1166. doi:10.1038/ajg.2011.43 CrossRefPubMed

Vincenzi B et al (2009) Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. Expert Opin Biol Ther 9:945–949. doi:10.1517/14712590903081694 CrossRefPubMed

Von Hoff DD et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691–1703. doi:10.1056/NEJMoa1304369 CrossRef

Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E (2009) Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol 135:1429–1435. doi:10.1007/s00432-009-0587-3 CrossRefPubMed

Yadav D et al (2009) Alcohol consumption, cigarette smoking, and the risk of recurrent acute and chronic pancreatitis. Arch Intern Med 169:1035–1045. doi:10.1001/archinternmed.2009.125 CrossRefPubMed

Yuge K, Miyajima A, Tanaka N, Shirotake S, Kosaka T, Kikuchi E, Oya M (2012) Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann Surg Oncol 19:3987–3993. doi:10.1245/s10434-012-2568-z CrossRefPubMed

Zou L et al (2014) Non-linear dose-response relationship between cigarette smoking and pancreatic cancer risk: evidence from a meta-analysis of 42 observational studies. Eur J Cancer 50:193–203. doi:10.1016/j.ejca.2013.08.014 CrossRefPubMed

Titel: The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients
verfasst von: Yousuke Nakai
Hiroyuki Isayama
Takashi Sasaki
Naminatsu Takahara
Kei Saito
Kazunaga Ishigaki
Tsuyoshi Hamada
Suguru Mizuno
Koji Miyabayashi
Keisuke Yamamoto
Dai Mohri
Hirofumi Kogure
Natsuyo Yamamoto
Hideaki Ijichi
Keisuke Tateishi
Minoru Tada
Kazuhiko Koike
Publikationsdatum: 01.05.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2015
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1873-2

Neu im Fachgebiet Onkologie

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients